Vascular Biogenics Ltd (VBLT)

NASDAQ
2.180
+0.040(+1.87%)
After Hours
2.300
+0.120(+5.505%)
- Real-time Data
  • Volume:
    145,261
  • Bid/Ask:
    2.130/2.300
  • Day's Range:
    2.110 - 2.200

VBLT Overview

Prev. Close
2.14
Day's Range
2.11-2.2
Revenue
1.45M
Open
2.11
52 wk Range
1.02-3.15
EPS
-0.53
Volume
145,261
Market Cap
120.09M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
536,108
P/E Ratio
-
Beta
0.98
1-Year Change
67.19%
Shares Outstanding
55,089,253
Next Earnings Date
Aug 16, 2021
What is your sentiment on Vascular Biogenics Ltd?
or
Market is currently closed. Voting is open during market hours.

Vascular Biogenics Ltd News

Vascular Biogenics Ltd Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyNeutralSellSell
Technical IndicatorsBuyStrong BuyStrong BuyStrong SellStrong Buy
SummaryStrong BuyStrong BuyBuyStrong SellNeutral

Vascular Biogenics Ltd Company Profile

Vascular Biogenics Ltd Company Profile

Employees
38

Vascular Biogenics Ltd., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer and immune/inflammatory indications. The company’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-511, an anti-angiogenic candidate for oncology; VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases; and VB-703 for NASH and renal fibrosis. In addition, the company is developing VB-201, a Lecinoxoid-based product candidate to treat atherosclerosis that has completed Phase II clinical; and is in Phase II exploratory trials for COVID-19, as well as in pre-clinical stage for the treatment of NASH and renal fibrosis. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi’in, Israel.

Read More
  • waiting good news definitely!👍
    0
    • good job!, congratulations!
      0
      • the Big Risk in Life is not to lose some money , Big Risk It is not investigate and not try to be better..
        0
        • big opportunity if buy and hold..besides science interesting
          0
          • we trust in projects of this company, really amazing ..
            0
            • waiting news about this beautiful company and investing a lot...hold and up!
              0
              • sorry actually day after tomorrow
                0
                • phase 3 report tomorrow
                  0
                  • new to this stock what's going on with it
                    0
                    • new to this stock what's going on with it
                      0
                      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.